Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

NCT03905343 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

25

Enrollment

OTHER

Sponsor class

Stopped Feasibility (low patient accrual and financial reasons)

Conditions

Breast Cancer

Interventions

DRUG: Ribociclib
OTHER: Mono-chemotherapy
OTHER: Endocrine-Therapy

Sponsor

Swiss Cancer Institute

Collaborators

[object Object]